Non Human Primate Study Demonstrates Unprecedented 70% Prevention of Infection

University of Alabama at Birmingham to Serve as Second Site for Ongoing Clinical Trial

The grant was awarded following GeoVax's submission for consideration of its HIV/AIDS vaccine research and development project to the U.S. Secretary of Health and Human Services.

Because of the difficulty raising antibodies that are capable of totally blocking natural HIV infections, the GeoVax vaccine approach has focused on raising cellular immune responses in addition to antibodies.

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical firm (the "Company") developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced its financial results and provided an update.

GeoVax is developing a vaccine that presents the natural form of HIV envelope proteins to the immune system on virus-like particles with the envelope proteins present in clusters of three, a confirmation known as trimers.

Since 1995, National HIV Testing Day has united organizations across the nation every June 27th to promote the early diagnosis of HIV.